Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"
Change 5d. change 1-year change 3-years change Capi.($)
+1.56%-6.83% - - 2.1M
+1.82%-0.94%+15.96%+218.25% 901B
+0.91%-2.40%+45.53%+60.40% 585B
-1.16%-2.91%+6.14%+54.36% 402B
+1.59%-4.70%+10.18%+28.47% 341B
+1.04%-2.74%+21.27%+64.75% 307B
+1.76%-1.51%+24.19%+37.46% 300B
+1.14%-3.54%+23.73%+8.84% 290B
+2.01%-2.26%+16.04%+66.96% 203B
+1.88%-2.27%+24.89%+85.73% 182B
Average +0.93%-3.51%+20.88%+69.47% 390.06B
Weighted average by Cap. +0.69%-3.10%+21.47%+92.97%
Logo VIVUS, Inc.
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
Employees
-
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW